Brought to you by 
Lee's Pharmaceutical gets Asian rights to RegeneRx's RGN259, RGN352, and RGN137
30 Jan 2023
Executive Summary
RegeneRx Biopharmaceuticals Inc. (therapeutics for unmet medical conditions) has granted Lee’s Pharmaceutical Holdings Ltd. rights in China (including Hong Kong and Macau) and Taiwan to several thymosin beta 4-based drug candidates: RGN259, RGN352, and RGN137.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lee's Pharmaceutical gets Asian rights to RegeneRx's RGN259, RGN352, and RGN137
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice